EGFR and cancer: The linear GE11 dodecapeptide YHWYGYTPQNVI was selected against the purified human EGFR protein and tested in EGFR-positive cancer cells and tumor xenografts [40] and was further conjugated to different drug delivery nanocarriers for targeting liver, ovarian and colorectal cancers [41,42,43].